Herzuma

Herzuma is a prescription intravenous solution that contains the monoclonal antibody trastuzumab as its active ingredient. It is supplied in a sterile liquid formulation for infusion and is marketed in the European Union. As a targeted antineoplastic agent, Herzuma is designed to bind the HER2 receptor on cancer cells, helping to inhibit tumor growth. The product is administered under the supervision of a qualified health‑care professional.

Herzuma is indicated for the treatment of several HER2‑positive malignancies. It is used in both metastatic and early‑stage disease settings as part of a prescribed therapeutic regimen.

- HER2‑positive metastatic breast cancer - HER2‑positive early breast cancer (adjuvant or neoadjuvant) - HER2‑positive gastric adenocarcinoma - HER2‑positive gastro‑esophageal junction adenocarcinoma - Combination with chemotherapy in approved protocols

Adverse reactions to Herzuma have been observed in clinical studies and post‑marketing experience. They can be grouped by frequency and severity.

Common: - Infusion‑related reactions (fever, chills, flushing) - Nausea or vomiting - Fatigue - Headache

Serious: - Cardiac dysfunction or decreased left ventricular ejection fraction - Severe hypersensitivity or anaphylaxis - Pulmonary toxicity (interstitial pneumonitis) - Thromboembolic events

Before initiating Herzuma, clinicians should evaluate patient history and monitor specific clinical parameters to reduce the risk of complications.

- Assess baseline cardiac function (e.g., echocardiogram) and repeat periodically. - Review prior trastuzumab exposure or hypersensitivity reactions. - Monitor for signs of infusion‑related reactions during and after administration. - Use caution in patients with pre‑existing pulmonary disease. - Avoid use in pregnant women; discuss contraception and potential fetal risk. - Adjust treatment in patients with hepatic impairment as recommended. - Counsel patients on the importance of reporting new cardiac symptoms promptly.

Herzuma may interact with other medicines that affect cardiac function or immune response. Relevant interactions are summarized below.

Avoid: - Concurrent use with anthracyclines (e.g., doxorubicin) due to increased cardiotoxicity risk. - Live vaccines during treatment because of immunosuppression.

Use with caution: - Other HER2‑targeted agents (pertuzumab, lapatinib) may increase toxicity. - Medications that prolong QT interval. - Drugs that cause significant hepatic enzyme induction or inhibition.